Biomarker to Enable Eradication of CML Stem Cells

By targeting CSC in specific tumor niches, this invention may present a novel and effective means of treating cells that have evaded eradication by other therapies. Unlike other approaches, this method:accounts for and compensates for the heterogeneity of most tumors;targets cancer stem cells, as opposed to the diverse, bulk population; and clarifies the relevance of cell cycle status within the tumor niche.

UC researchers have found that non-cycling stem cells in protected niches express distinctive patterns of Bcl-2 mRNA isoforms. Such information on cell cycle status and isoform profile may yield: A predictive biomarker for CSC drug susceptibility; A determination of cancer prognosis and progression; and An indicator of patient CSC response to anti-cancer therapies. l cycle status and isoform profile may yield:A predictive biomarker for CSC drug susceptibility; A determination of cancer prognosis and progression; and An indicator of patient CSC response to anti-cancer therapies.

Disease Diagnostic/Treatment

Cancer/Tumor

9194862

State Of Development

Inventors have identified characteristic ratios of specific, Bcl-2 family, mRNA-splice isoforms, which differ between tumor cell populations that are:

• ·         within vs. not in protected, tumor niches;
• ·         either CSC vs. normal cells, over the course of treatment; and
• ·         at various stages of the cell cycle.

Intellectual Property Info

Worldwide rights available for licensure (See WO2013070807)

Related Materials

Jamieson C.H.M. et al., (2008) Miscreant myeloproliferative disorder stem cells. Leukemia 22:2011-9.
Jamieson CH, et. al., (2004) Chronic versus acute myelogenous leukemia: a question of self-renewal, Cancer Cell, 6(6):531-3.
Jamieson CH, et. al., (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML, N Engl J Med., 351(7):657-67.
Catriona Jamieson, M.D., Ph.D. Associate Professor of Medicine.
Crews, L.A. and C. H. Jamieson, (2012) Chronic Myeloid Leukemia Stem Cell Biology, Curr Hematol Malig Rep., 7(2):125-32.
Goff, DJ, et al. (2012) A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition, Cell Stem Cell, 12(3):316-28
• Jamieson C.H. (2008) Chronic Myeloid Leukemia Stem Cells. Hematology 1:436-42.

Related Technologies

• Compositions and Methods for Determining Cancer Stem Cell Self-Renewal Potential

Tech ID/UC Case

22549/2012-155-0

Related Cases

2012-155-0, 2009-187-0

USA

Desktop View